Research Issues 26

Total Page:16

File Type:pdf, Size:1020Kb

Research Issues 26 If you have issues viewing or accessing this file contact us at NCJRS.gov. Research Issues --2 Guide to Drug Abuse Research Terminology u.s. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration Notional Inslitute on Drug Abuse L....t___________ ---""' ______ ~,· ~---". • RESEARCH ISSUES SERIES 1. Drugs and Employment 2. Drugs and Sex 3. Drugs and Attitude Change 4. Drugs and Family/Peer Influence 5. Drugs and Pregnancy 6. Drugs and Death 7. Drugs and Addict Lifestyles 8. A Cocaine Bibliography-Nonannotated 9. Drug Themes in Science Fiction 10. Drug Themes in Fiction 11. Predicting Adolescent Drug Abuse 12. Drug Abuse Instrument Handbook 13. Data Analysis Strategies and Designs for Substance Abuse Research 14. Drugs and Personality 15. Cocaine-Summaries of Psychosocial Research 16. The Lifestyles of Nine American Cocaine Users-Summary 17. Drugs and Crime 18. Drug Users and the Criminal Justice System 19. Drugs and Psychopathology 20. Drug Users and Driving Behaviors 21. Drugs and Minorities 22. Research Issues Update, 1978. 23. I nternational Drug Use 24. Perspectives on the History of Psychoactive Substance Use 25. Use and Abuse of Amphetamine and its Substitutes 26. Guide to Drug Abuse Research Terminology 27. Guide to the Drug Research Literature 28. Assessing Marijuana Consequences: Selected Questionnaire Items 29. Drugs and the Family Cover Illustration by Sumishta Brahmin, copyright 1978. Used by permission of the artist. Further reproduction is prohibited without permission of the artist. <0' I ,'J Research Issues 26 Guide to Drug Abuse Research Terminology Edited by Jack E. Nelson 89255 U.S. Department of Justice Helen Wallenstein Pearson National Institute of Justice This document has been reproduced exactly as received from the Mollie Sayers pers~n or organization originating it. Points of view or opinions stated In thiS document, ~re tho.~e of the authors and do not necessarily represent the offiCial position or policies of the National Institute of Thomas J. Glynn Justice. Permission to reproduce this CCpfAgPttect material has been .,graT\t.ed bjl • PUD~~C Domaln/U.S. Department 1982 OI1fecrhl1 & H~ to the National Criminal Justice Reference Service (NCJRS). ~urther reproduc,tion outside of the NCJRS system requires permis­ sion of the CQ""nglil Owner. U.S. OEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, M D 20857 r------------------------------------------------------------ I :The U. S. Government does not endorse or favor any specific commercial product or commodity. Trade or proprietary names appearing in this publication are used only because they are con­ sidered essential in the context of the studies reported herein. Material contained in this volume except for copyrighted material is in the public domain, and may be used and reprinted without obtaining permission from the Institute or the author. Cita­ tion as to source is appreciated. Permission has been obtained from the copyright holders to reproduce certain quoted material. Further reproduction of these quotations is prohibited without specific permission of the copyright holder. Permission to quote has been obtained for the following copyrighted material: (Chaplin 1975)--pp. 12, 13,14,15,21,23,29,31,36,37-38,50,51,52,61,64,71,74,77, 79,80,81,89,94. From Dictionary of Psychology: New Revised Edition by James P. Chaplin. Copyright (c) 1975 by James P. Chaplin. Reprinted by permission of Dell Publishing Co., Inc. (Encyclopedia of Sociology 1981 )--pp. 5, 23, 26, 27, 38, 44, 46, 52, 53, 65, 83, 86, 97, 99. From Encyclopedia of Sociology, New & Updated. Guilford, Conn.: Dushkin Publishing Group, 1981. Copyright (c) 1981 by DPG Reference Publishing, Inc. Reprinted with permission. (Fairchild 1976)--pp. 26, 30, 51, 62, 74, 90, 99. From Fairchild, H.P., ed. Dictionary of Sociology and Related Sciences. Totowa, N.J.: Littlefield, Adams, 1976 (orig. pUb. 1944). Reprinted with permission from Philosophical Library Publishers, copyright holders. (Lingeman 1969)--pp. lll, 15-16, 21, 43, 49, 71, 72, 83, 84, 86, 99, 100. From Lingeman, R. Drugs From A to Z: A Dictionary. New York: McGraw-Hili, 1969. Copyright (c) 1969. Reprinted with permiSSion from McGraw-H ill Book Company. (Zadrozny 1959)--pp. 26, 27, 45, 46, 74, 80, 82, 86, 99. From Zadrozny, J. Dictionary of Social Science. Washington, D. C.: Public Affairs Press, 1959. Reprinted with permission. THE EDITORS: Jack E. NeLson, HeLen WaLLenstein Peai$on, and MoLLie Sayeps, of Metpotec, Inc., Washington, D.C., paPticipated in deveLoping this pubLication for the NationaL Institute on Drug Abuse under Contract No. 271-80-3720. Thomas J. GLynn, Ph.D.; Division of ReseaPch, NID~. serv~d as co-editor in deveLopment of the materiaLs, and as NIDA proJect off~cer. CONTENTS PREFACE v INTRODUCTION USE OF GU IDE 2 DRUG ABUSE RESEARCH TERMINOLOGY 4 REFERENCES 101 APPENDIXES 115 Appendix A: Drug Classification 116 Appendix B! Drug Slang Terms 121 Appendix C: Trade Names 121 Appendix D: Acronyms 129 fEB 10 1983 iii .'''' PREFACE The first volume of the Research Issues Series was published in November 1974. Since that time, 29 volumes have been published in this series by the Division of Research, National Institute on Drug AbusE". The primary objective of the Research Issues Series is to provide both lay and professional read­ ers comprehensive, yet succinct, information on topics of central interest to the drug abuse field. The approach frequently iJsed has been to r:-rovlde abstracts of the relevant literature on a par­ ticular topic. In other cases materials have been developed and written especially for the series. This volume falls in the latter category and addresses the need for a reference guide to the ter­ minology of the drug abuse field. It is based upon a draft compiled by Gregory Austin of the Southern California Research Institute and reviewed by an editorial board of drug experts whose names and affiliations are listed balow. The board members have not reviewed this extensively revised final edit.ion, and the editors, while gratefully acknowledging the seminal contribution of the board members, take major responsibility for any imprecision or errors that may" occur. Richard J. Bonnie, J. D. Howard B. Kaplan, Ph.D. University of Virginia Department of Psychiatry School of Law Baylor College of Medicine Charlottesville, Virginia Houston I Texas Marcelline Burns Dan J. Lettieri, Ph. D. Southern Cal ifornia Research Institute Psychological Sciences Branch Los Angeles, California Division of Research National Institute on Drug Abuse Sidney Cohen, M.D. Rockville,' Maryland Neuropsychiatric Inst:tute University of California--Los Angele:; Mary Macari Documentation ASSOciates, Inc. ·Peter Fehrenbach Los Angeles. Cal ifornia Graduate Student Departm~nt of Psychology Stanton Peele, Ph. D. University of Missouri Department of Health Education Columbia, Missouri Teachers College at Columbia University New York City George J. Huba, Ph.D. Department of Psychology Patricia B. Sutker, Ph. D. University of California--Los Angeles Chief, Psychology Service Veterans Administration Medical Center Bruce Johnson, Ph.D. New Orleans, Louisiana Research Scientist New York State Division of Substance Abuse Services New York City v I 6' INTRODUCTION The drug abuse field consists of an amalgam of medical i social, and psychological disciplines. This, in turn, reflects upon its terminology, which ranges from colorful slan'g to advanced bio­ medical nomenclature. The breadth of drug abuse terms is thus vast and varied--from 4-letter slang to 10-syllable chemicals and from conceptualizations based on street-wise hip to those taken from advanced molecular biomedicine. For example, a SOCiologist in the drug- field may be found observing a street dude who is taking care of business hussling bags of China White so he can cop some real good snow; an epidemiologist may be concerned about the balloon effect likely to occur with implementation of a supply reduction strategy; a doctor may prescribe nepenthes, soporifics, or ergogenics to help patients cope; and a biochemist may "be interested in studying ,the dose-response relationship of cholinergic agents on the parasympathetic nervous system. A vast array of drug users, dealers, clinicians, researchers, teachers, U.<:orists, politicians, and others related to the drug abuse field have produced a large lexicon of terms that vary from the simple, but often clever, to the ultracomplex. Many drug terms are ambiguous, especially slang, and their meanings may vary over time (e.g., blues, black beauties, white stuff, kif, narcotic). Other terms may be deadly concise but are often confUSing to lay readers and professionals alike (e.g., endorphin/enkephalin, agonist/antag-. onist, analgesic/anesthetic, congenerlligand). There frequently are slang and scientific terms for the same concept (e.g., to insufflate/to blow, to inject/to shoot up, diacetylmorphine hydro­ chloride/horse, smack, or junk). Some terms have exotic sounding names (e.g., sinsemilla, khat, etonitazene), and others though widely used are grossly imprecise (e.g., high, addiction, toler­ ance, drug abuse, treatment). Explosive discoveries in the field are producing new and rapidly evolving terms, many of which are not currently defined in dictionaries or other standard reference works. These terms are defined only in the research literature where they are being discussed and debated. Examples of this type. include the constantly expanding list of newly identified endogenous agonists, the newer urinalysis screening techniques, and the newer approaches to treatment. This Guide to Drug Abuse Research Terminology attempts to bring a major segment of the myriad assortment of terms found in the drug abuse field under one cover and to present in glossary form definitions of many of the drug abuse terms that have to date been described only in the research literature. It has been designed and written to serve as a convenient guide for those requiring brief, nontechnical explanations of drug abuse terms.
Recommended publications
  • AND DRUG' ABUSE' ( , \ I ., : for VOLUNTEER .AFTERCARE OFFICERS
    =£q, G& ~. ~I o II g ~ L>- ".,-~..- ". 'PR'OBATIQN AND AFTERCA'RE SERVICE " rI ! ,~ i I!' 0 i! ,1 u I', :( ~ II' 1 r :.:" I I) 'tbLLECTED ,READINGS ,~ ~ - '., ,\ ON It, DR!J.GS ·AND DRUG' ABUSE' ( , \ i ., : FOR VOLUNTEER .AFTERCARE OFFICERS. ri ll, "' , 'I: o '.> .. , 4 . , . I:o..-__________:i-.._---... __ ~~ ___~;L __~ ______ fF PROBATION AND AFTERCARE SERVICE COLLECTED READUNGS ON DRUGS AND DRUG ABUSE FOR VOLUNTEER AFTERCARE OFFICERS 1977 a If' t «(, CONTENTS ARTICLE PAGE PART I - THE DRUG SCENE Speech by Dr Goh Keng Swee, Deputy Prime Minister and Minister of Defence, at the Launching of the NADAC Month at the National Theatre Or! Wedr!e~dev, 4th August 1976. 1 II Speech by Mr Chua Sian Chin, Minister for Home Affairs and Education at the Opening Ceremony of the First Meeting of ASEAN Drug Experts at the Crystal Ballroom, Hyatt Hotel, on Tuesday, 26th October 1976. 6 PART II - PREVENTIVE EDUCATION III The Objectives of Anti-Drug Abuse Education by Dr Tow Siang Hwa, Past President, Singapore Anti-Narcotics Association 8 .. PART III - DRUGS AND THEIR EFFECTS IV CommonlY Abused Drugs by Dr Yeow Teow Seng, Associate Profassor oi Pharmacology, University of Singapore 12 V The Non-Medical Uses of Dependence-Producing Drugs by Dr Leong Hon Koon 18 VI Psychiatric Aspects of Drug Abuse by Dr Paul W Ngui, Consultant Psychlatrist 23 VII Sad End to All Drug Trips by Dr Chao Tzu Cheng, Senior Forensic Pathologist, Ministry of Health 27 PART IV - SOCIAL CONSIDERATIONS OF DRUG ABUSE VIII Patterns & Social Consequences of Drug Abuse & the Rehabilitation of Drug Addict by K V Veloo, Chief Probation & Aftercare Officer 29 IX Social Factors of Drug Abuse by K V Veloo, Chief Probation & Aftercare Officer 34 f X Some Causes of Adolescent Problems , by S Vasoo, Deputy Director, Singapore Council of Social Service 39 " ,.
    [Show full text]
  • MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019
    1 ANTIEMETIC GUIDELINES: MASCC/ESMO MASCC/ESMO ANTIEMETIC GUIDELINE 2016 With Updates in 2019 Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex Molassiotis, RN, PhD Fausto Roila, MD © Multinational Association of Supportive Care in CancerTM All rights reserved worldwide. 2 ANTIEMETIC GUIDELINES: MASCC/ESMO These slides are provided to all by the Multinational Association of Supportive Care in Cancer and can be used freely, provided no changes are made and the MASCC and ESMO logos, as well as date of the information are retained. For questions please contact: Matti Aapro at [email protected] Chair, MASCC Antiemetic Study Group or Alex Molassiotis at [email protected] Past Chair, MASCC Antiemetic Study Group 3 ANTIEMETIC GUIDELINES: MASCC/ESMO Consensus A few comments on this guideline set: • This set of guideline slides represents the latest edition of the guideline process. • This set of slides has been endorsed by the MASCC Antiemetic Guideline Committee and ESMO Guideline Committee. • The guidelines are based on the votes of the panel at the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015. • Latest version: March 2016, with updates in 2019. 4 ANTIEMETIC GUIDELINES: MASCC/ESMO Changes: The Steering Committee has clarified some points: 2016: • A footnote clarified that aprepitant 165 mg is approved by regulatory authorities in some parts of the world ( although no randomised clinical trial has investigated this dose ). Thus use of aprepitant 80 mg in the delayed phase is only for those cases where aprepitant 125 mg is used on day 1. • A probable modification in pediatric guidelines based on the recent Cochrane meta-analysis is indicated.
    [Show full text]
  • Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update
    PAIN MANAGEMENT/CONCEPTS Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update Steven M. Green, MD, Mark G. Roback, MD, Robert M. Kennedy, MD, Baruch Krauss, MD, EdM From the Department of Emergency Medicine, Loma Linda University Medical Center and Children’s Hospital, Loma Linda, CA (Green); the Department of Pediatrics, University of Minnesota, Minneapolis, MN (Roback); the Division of Emergency Medicine, St. Louis Children’s Hospital, Washington University, St. Louis, MO (Kennedy); and the Division of Emergency Medicine, Children’s Hospital Boston and Department of Pediatrics, Harvard Medical School, Boston, MA (Krauss). We update an evidence-based clinical practice guideline for the administration of the dissociative agent ketamine for emergency department procedural sedation and analgesia. Substantial new research warrants revision of the widely disseminated 2004 guideline, particularly with respect to contraindications, age recommendations, potential neurotoxicity, and the role of coadministered anticholinergics and benzodiazepines. We critically discuss indications, contraindications, personnel requirements, monitoring, dosing, coadministered medications, recovery issues, and future research questions for ketamine dissociative sedation. [Ann Emerg Med. 2011;xx:xxx.] 0196-0644/$-see front matter Copyright © 2011 by the American College of Emergency Physicians. doi:10.1016/j.annemergmed.2010.11.030 INTRODUCTION thalamocortical and limbic systems, effectively dissociating the The dissociative
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/017.4603 A1 Abayarathna Et Al
    US 2016O174603A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/017.4603 A1 Abayarathna et al. (43) Pub. Date: Jun. 23, 2016 (54) ELECTRONIC VAPORLIQUID (52) U.S. Cl. COMPOSITION AND METHOD OF USE CPC ................. A24B 15/16 (2013.01); A24B 15/18 (2013.01); A24F 47/002 (2013.01) (71) Applicants: Sahan Abayarathna, Missouri City, TX 57 ABSTRACT (US); Michael Jaehne, Missouri CIty, An(57) e-liquid for use in electronic cigarettes which utilizes- a TX (US) vaporizing base (either propylene glycol, vegetable glycerin, (72) Inventors: Sahan Abayarathna, MissOU1 City,- 0 TX generallyor mixture at of a 0.001 the two) g-2.0 mixed g per with 1 mL an ratio. herbal The powder herbal extract TX(US); (US) Michael Jaehne, Missouri CIty, can be any of the following:- - - Kanna (Sceletium tortuosum), Blue lotus (Nymphaea caerulea), Salvia (Salvia divinorum), Salvia eivinorm, Kratom (Mitragyna speciosa), Celandine (21) Appl. No.: 14/581,179 poppy (Stylophorum diphyllum), Mugwort (Artemisia), Coltsfoot leaf (Tussilago farfara), California poppy (Eschscholzia Californica), Sinicuichi (Heimia Salicifolia), (22) Filed: Dec. 23, 2014 St. John's Wort (Hypericum perforatum), Yerba lenna yesca A rtemisia scoparia), CaleaCal Zacatechichihichi (Calea(Cal termifolia), Leonurus Sibericus (Leonurus Sibiricus), Wild dagga (Leono Publication Classification tis leonurus), Klip dagga (Leonotis nepetifolia), Damiana (Turnera diffiisa), Kava (Piper methysticum), Scotch broom (51) Int. Cl. tops (Cytisus scoparius), Valarien (Valeriana officinalis), A24B 15/16 (2006.01) Indian warrior (Pedicularis densiflora), Wild lettuce (Lactuca A24F 47/00 (2006.01) virosa), Skullcap (Scutellaria lateriflora), Red Clover (Trifo A24B I5/8 (2006.01) lium pretense), and/or combinations therein.
    [Show full text]
  • Substance Abuse and Dependence
    9 Substance Abuse and Dependence CHAPTER CHAPTER OUTLINE CLASSIFICATION OF SUBSTANCE-RELATED THEORETICAL PERSPECTIVES 310–316 Residential Approaches DISORDERS 291–296 Biological Perspectives Psychodynamic Approaches Substance Abuse and Dependence Learning Perspectives Behavioral Approaches Addiction and Other Forms of Compulsive Cognitive Perspectives Relapse-Prevention Training Behavior Psychodynamic Perspectives SUMMING UP 325–326 Racial and Ethnic Differences in Substance Sociocultural Perspectives Use Disorders TREATMENT OF SUBSTANCE ABUSE Pathways to Drug Dependence AND DEPENDENCE 316–325 DRUGS OF ABUSE 296–310 Biological Approaches Depressants Culturally Sensitive Treatment Stimulants of Alcoholism Hallucinogens Nonprofessional Support Groups TRUTH or FICTION T❑ F❑ Heroin accounts for more deaths “Nothing and Nobody Comes Before than any other drug. (p. 291) T❑ F❑ You cannot be psychologically My Coke” dependent on a drug without also being She had just caught me with cocaine again after I had managed to convince her that physically dependent on it. (p. 295) I hadn’t used in over a month. Of course I had been tooting (snorting) almost every T❑ F❑ More teenagers and young adults die day, but I had managed to cover my tracks a little better than usual. So she said to from alcohol-related motor vehicle accidents me that I was going to have to make a choice—either cocaine or her. Before she than from any other cause. (p. 297) finished the sentence, I knew what was coming, so I told her to think carefully about what she was going to say. It was clear to me that there wasn’t a choice. I love my T❑ F❑ It is safe to let someone who has wife, but I’m not going to choose anything over cocaine.
    [Show full text]
  • Cannabis (Sub)Culture, the Subcultural Repository, and Networked Mediation
    SIMULATED SESSIONS: CANNABIS (SUB)CULTURE, THE SUBCULTURAL REPOSITORY, AND NETWORKED MEDIATION Nathan J. Micinski A Thesis Submitted to the Graduate College of Bowling Green State University in partial fulfillment of the requirements for the degree of MASTER OF ARTS May 2014 Committee: Ellen Berry, Advisor Rob Sloane © 2014 Nathan Micinski All Rights Reserved iii ABSTRACT Ellen Berry, Advisor Subcultural theory is traditionally rooted in notions of social deviance or resistance. The criteria for determining who or what qualifies as subcultures, and the most effective ways to study them, are based on these assumptions. This project seeks to address these traditional modes of studying subcultures and discover ways in which their modification may lead to new understandings and ways of studying subcultures in the contemporary moment. This will be done by suggesting a change in the criteria of examining subcultures from that of deviance or resistance to identification with a collection of images, symbols, rituals, and narratives. The importance of this distinction is the ability to utilize the insights that studying subcultures can offer while avoiding the faults inherent in speaking for or at a subculture rather than with or from it. Beyond addressing theoretical concerns, this thesis aims to apply notions of subcultural theory to study the online community of Reddit, in particular, a subset known as r/trees–a virtual repository for those images, symbols, rituals, and narratives of cannabis subculture. R/trees illustrates the life and vibrancy of a unique subcultural entity, which to this point has evaded a cultural studies analysis. To that end, this project advocates for the importance of the cultural studies approach to analyzing cannabis subculture and further, to insert the findings of this study into that gap in the literature.
    [Show full text]
  • Sílvia Vilares Conde
    Sílvia Vilares Conde FUNCTIONAL SIGNIFICANCE OF ADENOSINE IN CAROTID BODY CHEMOSENSORY ACTIVITY IN CONTROL AND CHRONICALLY HYPOXIC ANIMALS Lisboa, 2007 a Dissertation presented to obtain the PhD degree in “Ciências da Vida – Especialidade Farmacologia” at the Faculdade de Ciências Médicas, Universidade Nova de Lisboa and Biotecnología: Aplicaciones Biomédicas at the Facultad de Medicina, Universidad de Valladolid Supervised by Profs. Constancio Gonzalez, Emília Monteiro and Ana Obeso. b Realizado com o apoio da Fundação para a Ciência e Tecnologia, SFRH/BD/14178/2003 financiada pelo POCI 2010 no âmbito da Formação avançada para a Ciência, Medida IV.3. c To my mum and dad d This work: Originated the following publications: - Conde S.V., Obeso A., Vicario I., Rigual R., Rocher A. and Gonzalez C. (2006), Caffeine inhibition of rat carotid body chemoreceptors is mediated by A2A and A2B adenosine receptors, J. Neurochem., 98, 616-628. (Chapter 3) - Conde S.V. and Monteiro E.C. (2006), Activation of nicotinic ACh receptors with α4 subunits induces adenosine release at the rat carotid body, Br. J. Pharmacol., 147, 783-789. (Chapter 2) - Conde S.V. and Monteiro E.C. (2004), Hypoxia induces adenosine release from the rat carotid body, J. Neurochem., 89 (5), 1148-1156. (Chapter 1) - Conde S.V. and Monteiro E.C. (2003), Adenosine-acetylcholine interactions at the rat carotid body, In: “Chemoreception: From cellular signalling to functional plasticity”, JM Pequinot et al. (Eds), Klumer Academic Press London, 305-311. (Chapter 2) Won the following awards: - 1st Prize “De Castro-Heymans–Neil Award” awarded by ISAC (International Society for Arterial Chemoreception) to the best work presented by a Young Researcher each triennial ISAC Meeting, 2002 - Pfizer Honor Young Researcher Prize awarded by the Portuguese Society of Medical Sciences, 2002 e Functional significance of adenosine in carotid body chemoreception PhD thesis, Silvia Vilares Conde INDEX Page List of Figures and Tables………………………………………………………..
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Lactuca Sativa
    Botanical Files on Lettuce (Lactuca sativa). On the chance for flow between wild and cultivated gene Lettuce (Lactuca sativa L. including L. serriola L., Compositae) and the generalized implications for risk-assessments on genetically modified plants by 12 2 ,3 F.T.+Frietema de Vriesi R. van der Meijdeni and W.A. Brandenburg , dit onderzoek werd door het Ministerie De opdracht tot gegeven van Volkshuisvesting, Ruimtelijke Ordening & Milieu, Directoraat-Generaal Milieu, Directie Stoffen, Veiligheid, Straling. De tekst het zal in de VROM/DGM Risico- van rapport verschijnen publicatiereeks beoordeling genetisch gemodificeerde organismen. This commissioned the Netherlands of report was by Ministry Housing, Spatial Planning and Environment, Directorate General for the Environment, Directorate for Chemicals, External Safety and Radiation Protection, P. O. Box 450, 2260 MB Leidschendam, The Netherlands. It will be published in the series Risk Assessment Genetically Modified Organisms. 1) Formerly F.T. de Vries 2) Rijksherbarium/Hortus Botanicus, Slate University Leiden, P.O. Box 9514, 2300 RA Leiden, The Netherlands 3) Centrum voor Plantenveredelings- en Reproduktieonderzoek, CPRO-DLO, P.O. Box 16, 6700 AA Wageningen,The Netherlands Contents Summary 3 1. Introduction 3 2. Lactuca serriolaL. and L. serriola L. in Western 6 Historical part: Europe... Introduction 6 Terminology 6 The genus Lactuca L 7 Genetics 8 Ancestors 9 Characters 9 3. Domestication of Lettuce 11 Introduction 11 Early domestication 11 of the different of cultivated lettuce Further development groups 12 4. Field trial 13 Introduction 13 Material 15 Methods 15 Observations 16 Herbarium material 16 Photography and microscopy 16 5. Results 17 Introduction 17 Results herbarium study 17 Results field trial 17 6.
    [Show full text]
  • A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L
    Hofstra Law Review Volume 18 | Issue 3 Article 10 1990 A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L. Galiber Follow this and additional works at: http://scholarlycommons.law.hofstra.edu/hlr Part of the Law Commons Recommended Citation Galiber, Joseph L. (1990) "A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation," Hofstra Law Review: Vol. 18: Iss. 3, Article 10. Available at: http://scholarlycommons.law.hofstra.edu/hlr/vol18/iss3/10 This document is brought to you for free and open access by Scholarly Commons at Hofstra Law. It has been accepted for inclusion in Hofstra Law Review by an authorized administrator of Scholarly Commons at Hofstra Law. For more information, please contact [email protected]. Galiber: A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with R A BILL TO REPEAL CRIMINAL DRUG LAWS: REPLACING PROHIBITION WITH REGULATION Joseph L. Galiber* Conventional wisdom obliges elected officials to beat the narcodrums loudly and incessantly, and to demand increasingly harsh criminal penalties for the sale and use of illegal drugs.' It is reasonable to wonder why I, a senator, would dare submit a bill2 to the New York State Legislature which would regulate all drugs cur- rently proscribed as illegal in precisely the same manner as alcohol.3 The short answer is that the use of the criminal law to control drug use has not, and never will, have anything more than a costly and marginal impact on drug consumption.4 Despite all the public hyperventilation, drug consumption remains a private, consensual * New York State Senator; B.A.
    [Show full text]
  • Innovation in Pain Management
    INNOVATION IN PAIN MANAGEMENT The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 12 December 2002 Edited by L A Reynolds and E M Tansey Volume 21 2004 ©The Trustee of the Wellcome Trust, London, 2004 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2004 The Wellcome Trust Centre for the History of Medicine at University College London is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 0 85484 097 7 Histmed logo images courtesy Wellcome Library, London. Design and production: Julie Wood at Shift Key Design 020 7241 3704 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Reynolds L A, Tansey E M. (eds) (2004) Innovation in Pain Management. Wellcome Witnesses to Twentieth Century Medicine, vol. 21. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Witness Seminars: Meetings and publications;Acknowledgements vii E M Tansey and L A Reynolds Introduction Christina Faull xix Transcript Edited by L A Reynolds and E M Tansey 1 Appendix 1 73 Extract from an annotated Physiological Society interview with Patrick Wall (1925–2001) by Martin Rosenberg and Steve McMahon (5 February 1999) Appendix 2 83 Morphine: Optimal potential for benefit with a minimum risk of adverse events and burden by Jan Stjernswärd (12 April 2004) References 85 Biographical notes 103 Index 115 Key to cover photographs ILLUSTRATIONS AND CREDITS Figure 1 Dr Cicely Saunders and two patients at St Joseph’s on their golden wedding anniversary, 1960.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]